These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 16189137

  • 21. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V, Söyletir G, Yalçın AN, Oğünç D, Dokuzoğuz B, Esener H, Ulusoy S, Tünger A, Aygen B, Sümerkan B, Arman D, Dizbay M, Akova M, Hasçelik G, Eraksoy H, Başaran S, Köksal I, Bayramoğlu G, Akalın H, Sınırtaş M.
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [Abstract] [Full Text] [Related]

  • 22. In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.
    Rödel R, Freyer A, Bittner T, Schäfer V, Hunfeld KP.
    Int J Antimicrob Agents; 2007 Jul; 30(1):83-6. PubMed ID: 17512703
    [Abstract] [Full Text] [Related]

  • 23. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M, Jones RN, Livermore DM.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [Abstract] [Full Text] [Related]

  • 24. Comparative review of the carbapenems.
    Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA.
    Drugs; 2007 Apr; 67(7):1027-52. PubMed ID: 17488146
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM, Brown SD.
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [Abstract] [Full Text] [Related]

  • 26. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [Abstract] [Full Text] [Related]

  • 27. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR, Niles AC.
    Diagn Microbiol Infect Dis; 1990 Feb; 13(1):57-61. PubMed ID: 2331851
    [Abstract] [Full Text] [Related]

  • 28. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
    Hoellman DB, Kelly LM, Credito K, Anthony L, Ednie LM, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2002 Jan; 46(1):220-4. PubMed ID: 11751138
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR, Sader HS, Stillwell MG, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [Abstract] [Full Text] [Related]

  • 30. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [Abstract] [Full Text] [Related]

  • 31. [Activity of doripenem against anaerobic bacteria].
    Dubreuil L, Neut C, Mahieux S, Muller-Serieys C, Jean-Pierre H, Marchandin H, Soussy CJ, Miara A.
    Pathol Biol (Paris); 2011 Apr; 59(2):102-7. PubMed ID: 20537808
    [Abstract] [Full Text] [Related]

  • 32. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE, Lindmark A, Persson I.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [Abstract] [Full Text] [Related]

  • 33. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
    Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.
    Antimicrob Agents Chemother; 2008 Feb; 52(2):761-6. PubMed ID: 18070958
    [Abstract] [Full Text] [Related]

  • 34. Doripenem: position in clinical practice.
    Dedhia HV, McKnight R.
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
    [Abstract] [Full Text] [Related]

  • 35. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes].
    Watanabe K, Kato N, Tanaka-Bandoh K, Tanaka Y, Kato H, Ueno K.
    Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627
    [Abstract] [Full Text] [Related]

  • 36. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [Abstract] [Full Text] [Related]

  • 37. Carbapenems: a potent class of antibiotics.
    Nicolau DP.
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [Abstract] [Full Text] [Related]

  • 38. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP, Pottumarthy S, Morris AJ.
    N Z Med J; 1999 Nov 12; 112(1099):424-6. PubMed ID: 10678225
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W, Pitkin DH, Nadler H.
    Clin Infect Dis; 1993 Jun 12; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.